At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 104 enrolled
Drug / intervention
AT-527 +1 moredrug
Likely dose
AT-527 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Antiviral Activity, Safety, Pharmacokinetics, and Efficacy of RO7496998 (AT-527) in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19
In Brief
A Phase 2 clinical trial evaluating AT-527 and Placebo for COVID-19. Completed, enrolled 104 participants across 12 sites in 6 countries.
Detailed Summary
This randomized study evaluates the antiviral activity, safety, efficacy and pharmacokinetics of AT-527 versus a placebo in participants with mild or moderate coronavirus disease (COVID-19) who are not hospitalized.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesCanada, Greece, Ireland, Latvia, Spain, United Kingdom
CollaboratorsAtea Pharmaceuticals, Inc.
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJan 2021
Enrollment StartFeb 2021
Primary CompletionSep 2021
Study CompletionOct 2021
TodayJul 2026
First PostedJan 14, 2021
Enrollment StartFeb 3, 2021
Primary CompletionSep 17, 2021
Study CompletionOct 13, 2021
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 5.5 years ago
Interventions
AT-527drug
Results from Arm AT-527 500 mg determined the dose and regimen to be used for AT-527 1100 mg.
Placebodrug
The dose and regimen of the placebo will match that of the respective AT-527 comparator arm.